12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

Summary

This is an open-label, multicenter study designed to assess the safety of intranasal administration of 400 μg of fluticasone propionate twice a day delivered by the OptiNose device in subjects with chronic sinusitis with or without nasal polyps. The study consists of an up-to-7-day pretreatment phase followed a 12-month open-label treatment phase. The duration of each subject's participation is approximately 53 weeks.

Timeline

Start

2013-09

Primary completion

2015-08

Completion

2015-10

Drugs

Indications